Researchers use multiomics analysis to understand how SARS-CoV-2 variants, including Alpha, Delta, and Omicron, modulate the host’s cellular responses and adapt to evade human immunity. The study highlights the potential for targeted therapies against both adaptive and innate immune responses.
CVS is willing to dump 10% of its Medicare Advantage members next year
CVS Health is preparing to make significant changes to its 2025 Medicare Advantage plans, which could potentially drive away 10% of its membership, the company’s
May 14, 2024